Raymond James Downgrades Phase Forward (PFWD) to Outperform
More News related to PFWD
- Piper Jaffray Downgrades Phase Forward (PFWD) to Neutral; Lack of Near-Term Catalysts
- Phase Forward (PFWD) Signs Multi-Yr, Multi-Million Dollar Contract with GlaxoSmithKline (GSK)
- Phase Forward Customer GlaxoSmithKline Signs Multi-Year Agreements
- Leerink Swann Resumed Healthcare Technology and Distribution Sector With Positive Bias
- Phase Forward's Russell J. Campanello Honored with STEVIE(R) Award for Human Resources Executive of the Year
More News related to Downgrades
- Jefferies Downgrades Discovery Lab (DSCO) Two-Notches To Underperform
- Credit Suisse Downgrades FPL Group (FPL) to Neutral
- Jefferies & Co Downgrades Blackbaud (BLKB) to Hold
- JP Morgan Upgrades Franklin Resources (BEN) and T.Rowe (TROW), Downgrades FII, EV
- Goldman Sachs Downgrades Group 1 Automotive (GPI) to Neutral On Valuation
Raymond James downgrades Phase Forward (Nasdaq: PFWD) from Strong Buy to Outperform.
Phase Forward Incorporated provides integrated enterprise-level software products, services, and hosted solutions for use in clinical trial and drug safety monitoring activities in the United States, the United Kingdom, France, and the Asia Pacific.
Related Categories
DowngradesStocks Mentioned
-0.63Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
